Cardiac Resynchronization Therapy (CRT) pacemakers and defibrillators - CRT Positive Left Ventricular Offset 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Boston Scientific 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2017-12-22
  • 사례 출판 날짜
    2017-12-22
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: boston scientific cardiac resynchronization therapy (crt) pacemakers and defibrillators - crt positive left ventricular offset medical device manufacturer, boston scientific, has issued a medical device safety alert concerning its cardiac resynchronization therapy pacemakers (crt-ps) and defibrillators (crt-ds). the affected crt devices are identified as the following:- valitude crt-p [models: u125 and u128] resonate crt-d [models: g424, g425, g426. g428, g437, g447, g448, g525, g526, g528, g537, g547, g548] momentum crt-d [models: g124, g125, g126, g128, g138] autogen crt-d [models: g160, g161, g166, g168, g172, g173, g175, g177, g179] inogen crt-d [models: g140, g141, g146, g148] visionist crt-p [models: u225, u226, u228] vigilant crt-d [models: g224, g225, g228, g237, g247, g248] charisma crt-d [models: g324, g325, g328, g337, g347, g348] dynagen crt-d [models: g150, g151, g156, g158] origen crt-d [models: g050, g051, g056, g058] the manufacturer has issued a field action product advisory to physician includes important programming information to prevent an unintended asynchronous biventricular (biv) pacing behavior when tracking elevated atrial intrinsic rhythms in certain crt-ps and crt-ds. according to the manufacturer, repeated detection of the unintended asynchronous biv pacing behavior may result in the implanted device reverting to a permanent safety mode (safety core) status thus requiring early replacement. the unintended asynchronous biv pacing behavior can only occur when an infrequent combination of parameters is programmed, specifically: left ventricular (lv) offset programmed to a positive value which exceeds the atrial blank after ventricular pace (a-blank after v-pace) interval; and tracking preference = on (nominal). until software is available to prevent programming of a susceptible combination of parameters, the advisory’s programming recommendations eliminate the risks associated with early device replacement due to the device behavior. crt devices more commonly programmed to simultaneous biv pacing (lv offset = zero) or sequential biv where lv precedes rv (negative lv offset value) are not subject to the risks described in the advisory the manufacturer is actively developing a software update designed to prevent programming of a susceptible combination of parameters. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 22 december 2017.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Boston Scientific Cardiac Resynchronization Therapy (CRT) pacemakers and defibrillators - CRT Positive Left Ventricular Offset
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”
  • Source
    DH